End-of-Detox Benzodiazepine Immunoassay Levels Did Not Prove the Cause of Later Relapse

Persistent analytical signal and a proposed delayed-withdrawal mechanism are separate evidentiary steps.

What the supplied source reports

The study measured serum benzodiazepine signal by radioimmunoassay near the end of diazepam-based treatment for moderate alcohol withdrawal. Levels correlated with dosing and cessation timing. The author proposed that residual exposure might mask the transition to lower concentrations after discharge.

Limits and uncertainty

A class-oriented immunoassay is not the same as separately quantifying diazepam and each active metabolite. The proposed relationship with later symptoms or relapse requires outcome evidence beyond residual levels. Therapeutic concentrations also need clinical context rather than automatic labeling as impairment.

Implications for forensic review

For a detoxification timeline, distinguish last dose, persisting parent or metabolite exposure, observed symptoms and actual relapse. Explain the assay’s calibration and cross-reactivity. The paper supports attention to delayed elimination but cannot establish that residual benzodiazepine exposure caused an individual post-discharge event.

Source and related reading

Source reviewed: High levels of benzodiazepines after treatment of moderate alcohol withdrawal syndrome the problem o (PMC9881567). Forensic applications above are interpretive analysis of the supplied publication.

Related reading: A Lorazepam Response in a Cannabis-Associated Catatonia Case Did Not Prove Cannabis Causation.